colleagues report the results of their study of sentinel lymph node mapping in very low-risk melanoma patients. These 50 patients had Clark level II or III, non-ulcerated thin (£0.75 mm) melanomas with regression. As in our study, they found no evidence that the presence of regression should be used to lower the threshold for sentinel lymph node mapping. We thank the investigators for bringing their findings to our attention and trust that, with these two studies, patients with low-risk melanoma will be spared unnecessary surgical interrogation of regional lymph nodes.
